Dermatology
Conference Coverage
Abrocitinib highly effective as long-term monotherapy in AD
JADE EXTEND study shows nearly 90% EASI-75 rate at 48 weeks.
Conference Coverage
Topical tapinarof effective in pivotal psoriasis trials
Efficacy was comparable with potent topical corticosteroids, but without the side-effects baggage.
Feature
Twelve medical groups pen letter opposing UHC copay accumulator program
“We see policies like this as sacrificing patients to the battle over high drug prices,” said Dr. Christopher Phillips.
Conference Coverage
Hand eczema: Pan-JAK inhibitor delgocitinib shows dose-dependent response in phase 2b trial
“By mode of action, we think delgocitinib is more selective in the way of acting.”
News from the FDA/CDC
Systemic sclerosis patients share their perspectives and needs in treatment trials
FDA officials and clinical researchers heard about the impact that different symptoms have on patients’ daily lives in order to design better...
From the Journals
Baricitinib reduces adult atopic dermatitis severity in phase 3 study
In moderate to evere AD, baricitinib 4 mg on top of topical corticosteroids significantly reduced signs and symptoms.
From the Journals
New lupus classification criteria perform well in children, young adults
A new study upholds the accuracy of the 2019 ACR-EULAR classification criteria in patients aged 21 years and younger.
Conference Coverage
Study highlights differences between White and Latino patients with psoriasis
Latinos had a higher mean percentage of body surface area involvement in the upper limbs.
From the Journals
Shingrix effective in older adults with preexisting immune-mediated disorders
The most common immune-mediated disorders in two phase 3 clinical trials of the vaccine were psoriasis, spondyloarthropathy, rheumatoid arthritis...
Feature
Pregnancy studies on psoriasis, PsA medications pick up
OTIS has enrolled women with psoriasis and/or psoriatic arthritis in studies of nine medications, most of them biologics.
From the Journals
Review finds evidence for beta-blockers for some rosacea symptoms
A systematic review provides limited evidence to support oral beta-blockers as a treatment for rosacea-associated facial erythema and flushing.